Peter Feinberg Biography and Net Worth

Director of Immuneering

Mr. Feinberg has served on our Board of Directors since January 2021. Mr. Feinberg was a Founding Member of Boxcar Partners, a venture capital investment firm with a focus on biotechnology investing, and has served as Partner there since 2019. Mr. Feinberg is also a Founder of Sporos Bioventures, LLC, a private biotechnology company focused on transforming the drug development process across oncology. In addition, he currently serves as Co-Founder of BridgeBio Pharma, Inc., a publicly traded biotechnology company focusing on genetic diseases, Boxcar PMJ LP and Emerging Security Solutions. He has more than three decades of experience in the financial services industry at Oppenheimer & Co. Inc. where he served as a Managing Director. Mr. Feinberg served on the board of directors of Notable Labs, LTD., a publicly traded biotechnology company, from September 2023 to October 2024. Mr. Feinberg received his B.S. in finance from Whittier College.

What is Peter Feinberg's net worth?: The estimated net worth of Peter Feinberg is at least $714.04 thousand as of January 12th, 2026. Mr. Feinberg owns 135,441 shares of Immuneering stock worth more than $714,045 as of May 5th. This net worth approximation does not reflect any other investments that Mr. Feinberg may own. Learn More about Peter Feinberg's net worth.
How do I contact Peter Feinberg?: The corporate mailing address for Mr. Feinberg and other Immuneering executives is , , . Immuneering can also be reached via phone at 617-500-8080 and via email at [email protected]. Learn More on Peter Feinberg's contact information.
Has Peter Feinberg been buying or selling shares of Immuneering?: Peter Feinberg has not been actively trading shares of Immuneering during the last quarter. Most recently, on Monday, January 12th, Peter Feinberg bought 20,000 shares of Immuneering stock. The stock was acquired at an average cost of $4.35 per share, with a total value of $87,000.00. Following the completion of the transaction, the director now directly owns 135,441 shares of the company's stock, valued at $589,168.35. Learn More on Peter Feinberg's trading history.
Who are Immuneering's active insiders?: Immuneering's insider roster includes Peter Feinberg (Director), Diana Hausman (Director), and Benjamin Zeskind (CEO). Learn More on Immuneering's active insiders.
Are insiders buying or selling shares of Immuneering?: In the last year, Immuneering insiders bought shares 21 times. They purchased a total of 200,126 shares worth more than $712,543.52. The most recent insider tranaction occured on January, 16th when insider Harold Eugene Brakewood bought 5,250 shares worth more than $24,990.00. Insiders at Immuneering own 22.9% of the company. Learn More about insider trades at Immuneering.
Information on this page was last updated on 1/16/2026.

Peter Feinberg Insider Trading History at Immuneering

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/12/2026	Buy	20,000	$4.35	$87,000.00	135,441
10/3/2025	Buy	7,500	$6.67	$50,025.00	156,766
9/30/2025	Buy	7,500	$7.03	$52,725.00	149,266
9/29/2025	Buy	5,000	$7.18	$35,900.00	141,766
6/18/2025	Buy	25,000	$2.53	$63,250.00	136,766
3/22/2024	Buy	25,000	$2.55	$63,750.00	111,766

Peter Feinberg Buying and Selling Activity at Immuneering

Immuneering Company Overview

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Today's Range

Now: $5.34

$5.16

$5.51

50 Day Range

MA: $5.31

$4.78

$6.13

2 Week Range

Now: $5.34

$1.10

$10.08

Volume

679,085 shs

Average Volume

1,396,706 shs

Market Capitalization

$345.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37